about
Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patientsExtended-schedule dose-dense temozolomide in refractory gliomasCirculating endothelial cells and procoagulant microparticles in patients with glioblastoma: prognostic value.Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma PatientsUsefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyCirculating endothelial and endothelial progenitor cells in non-small-cell lung cancer.Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study.A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.Erratum: Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study.Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas.Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience.ATCT-05OBJECTIVE RESPONSE (OR) TO NEOADJUVANT TREATMENT IN GLIOBLASTOMA AND ITS IMPACT ON OVERALL SURVIVAL (OS). A META-ANALYSIS OF NEOADJUVANT TRIALS OF THE SPANISH GROUP FOR RESEARCH IN NEUROONCOLOGY (GEINO).P17.04RANO CRITERIA APPLIED TO A PHASE II RANDOMIZED, MULTICENTER TRIAL COMPARING TEMOZOLOMIDE (TMZ) VS TMZ-PLUS-BEVACIZUMAB (BEV) BEFORE STANDARD TREATMENT IN UNRESECTABLE GLIOBLASTOMA (GBM) PATIENTS (P).GENOM 009 STUDY BY THE GEINO GROUP.P18.08A MULTICENTRIC, OBSERVATIONAL, NON INTERVENTIONAL STUDY OF EFFICACY AND SAFETY OF LACOSAMIDE FOR THE TREATMENT OF EPILEPTIC SEIZURES IN PATIENTS WITH BRAIN TUMORS.Radium-223 international early access program: results from the Spanish subset.SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).Correction to: SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience.Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.[Burkitt's lymphoma in relation to acquired immunodeficiency syndrome (AIDS)][Extragonadal germinal tumor syndrome]Extragonadal germ cell tumors: prognostic factors and long-term follow-upToxic epidermal necrolysis associated with interleukin-2Primitive neuroectodermal kidney tumorSunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
P50
Q28246500-05DCCF06-523C-4454-B228-6485C6FB1598Q33385736-6FB3FAF2-CB5A-4265-B4A5-5B24A7FE944BQ34902070-3D63631A-35C3-4259-BE73-DB6FCD4B4ECBQ36111620-0AD4CAB4-CE6D-4341-9EC7-C8AB7224880DQ36959180-B8D0EED5-F1C1-4547-9FCC-D6A94B4A156CQ37780014-B0CD11B4-1498-473B-A341-ED3E03B381AEQ38188423-44FC1D76-9525-4385-9AE7-E82419EDC2A6Q38733792-85A5F755-6B76-4E76-955B-3A25514FA8C4Q41701813-63DE7DE9-7975-4765-9225-0560EC4FE5FDQ42128311-34B57BE1-A36A-4A60-AC27-F5D2D626710BQ42366771-A5CBD995-92C2-4F99-AF00-E1EE5154A900Q43230421-902BE5A1-4B2C-4C49-AAD5-EC330C4382D5Q43505131-EC62AE6E-BD19-4EA1-A9EE-3A9E66AE8030Q44720064-D43DE8DE-0114-47AF-8831-B93DDB87072AQ45265275-720E2959-9F69-43CC-920A-B51E64A3542EQ45831059-B677AC54-482B-4FBE-8349-CCDA9DAAEEA4Q46661236-BC1BA4EA-E6D5-40E4-8399-E530E97BA255Q46886182-498C99B0-05B1-486B-8B5C-3E75C05FF223Q47786425-148C130D-85E1-44F2-B883-7F08A00C587AQ47976126-300FD939-18FC-4713-BC71-23C09649018CQ48170755-8C59B6F5-5940-4C5F-A23F-EF3DBA16D04DQ48925984-8113F468-83D7-4AA0-8F5F-86239CFCEE95Q51760380-AACF267B-89CF-4068-989D-95ACD687AE0CQ52146796-317C5C79-0467-45B8-9D23-6FB6EF18380CQ53819906-C9A1F889-EFFB-4FC2-9E54-71DD77741389Q53838239-377A81EC-FEC9-4AD7-AD51-3A34C169230DQ55461272-B5A5BFD9-B034-4F66-90A0-F739111E0131Q55461341-69A445FE-025B-4E27-B4B1-470BCF8C4D9CQ68974287-688BE0BB-B8DB-4001-AAEE-CE9112F298E0Q70141236-040C793B-5C70-4531-8AA7-0C7743BE319BQ70788076-DFE7BE9C-01DC-47F3-9396-080F3C0EA68FQ74371744-5FD4FC27-E162-4FFF-80BF-211B516DA16FQ77551255-A2A8BAE7-F1CA-440C-BF2B-B7A2780191E9Q92327888-4125533D-08CF-493A-9F43-E4D3595BD421
P50
description
researcher
@en
name
Gaspar Reynés
@en
Reynés G
@ast
Reynés G
@nl
type
label
Gaspar Reynés
@en
Reynés G
@ast
Reynés G
@nl
altLabel
Reynés G
@en
prefLabel
Gaspar Reynés
@en
Reynés G
@ast
Reynés G
@nl
P106
P31
P496
0000-0001-8636-6094